Equities

Exagen Inc

Exagen Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.96
  • Today's Change0.11 / 3.86%
  • Shares traded34.29k
  • 1 Year change+27.04%
  • Beta1.3184
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Exagen Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a 102.70% increase from the last price of 2.96.
High170.3%8.00
Med102.7%6.00
Low68.9%5.00

Earnings history & estimates in USD

On Aug 05, 2024, Exagen Inc reported 2nd quarter 2024 losses of -0.16 per share. This result exceeded the -0.35 consensus loss of the 6 analysts covering the company and exceeded last year's 2nd quarter results by 42.86%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+10.95%
Exagen Inc reported annual 2023 losses of -1.34 per share on Mar 18, 2024.
Average growth rate+12.18%
More ▼

Revenue history & estimates in USD

Exagen Inc. had 2nd quarter 2024 revenues of 15.06m. This bettered the 13.13m consensus of the 6 analysts covering the company. This was 34.14% above the prior year's 2nd quarter results.
Average growth rate+1.68%
Exagen Inc. had revenues for the full year 2023 of 52.55m. This was 15.33% above the prior year's results.
Average growth rate+7.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.